Reaction
Nail Growth Abnormal reporting signals
As of the last recalculation, Nail Growth Abnormal appears in 1,091 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is THYROID, PORCINE (PRR 21.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Thyroid, Porcine | 12 | 21.7 | 21.7 |
| Ibrutinib | 76 | 19.2 | 19.2 |
| Felodipine Extended-Release Tablets | 11 | 18.6 | 18.6 |
| Felodipine | 11 | 18.6 | 18.6 |
| Osimertinib | 20 | 12.1 | 12.1 |
| Teriparatide | 59 | 10.5 | 10.5 |
| Abaloparatide | 15 | 9.8 | 9.9 |
| Levocetirizine Dihydrochloride | 12 | 9.6 | 9.6 |
| Niraparib | 10 | 8.7 | 8.7 |
| Erlotinib | 4 | 7.9 | 7.9 |
| Palbociclib | 36 | 7.4 | 7.4 |
| Abemaciclib | 7 | 6.7 | 6.7 |
| Teriflunomide | 15 | 6.4 | 6.4 |
| Lapatinib | 5 | 6.2 | 6.2 |
| Abiraterone | 4 | 5.6 | 5.6 |